By M. Marin
OTCQB:AINMF
READ THE FULL AINMF RESEARCH REPORT
Several agreements announced recently to leverage company’s AI technology to help optimize drug development clinical trial outcomes…
NetraMark (OTCQB:AINMF), an Artificial Intelligence (AI) company focused on the development of AI and Machine Learning (ML) solutions to support the pharmaceutical industry’s ability to optimize clinical research activities, has formed several agreements recently to leverage its growing portfolio of solutions and tools as it uses algorithms to analyze patient data generated during a live clinical trial and identify specific subpopulations that might negatively impact clinical trial outcomes to help pharma companies derisk clinical trials and increase their efficiency. NetraMark anticipates that its insights potentially could protect millions of dollars of invested capital. The company announced several agreements recently to leverage its growing portfolio and believes its solutions will increase success rates for drug sponsors and shorten the time to commercialization.
Pharmaceutical and medical device companies and other entities that conduct clinical trials are ‘sponsors’ of new therapies or medical devices. Many sponsors outsource portions or all activities related to a trial to a clinical research organization, designating the CRO to manage the clinical trial process. CROs then conduct the daily research activities on behalf of the sponsor. NetraMark has a growing pipeline of leads and has already closed.
Partnership with Worldwide Clinical Trials CRO
With its growing toolkit that leverages AI, the company expects to leverage two paths to commercialization: working directly with sponsors, including pharmaceutical companies, and partnering with CROs. In April 2025, NetraMark entered into a global agreement with CRO Worldwide Clinical Trials to introduce a new service offering for Worldwide's customers, powered by NetraMark's NetraAI platform to optimize clinical trial efficiencies. Worldwide Clinical Trials is a full-service global CRO with a footprint that reaches more than 60 countries. Worldwide has about 30 years of clinical experience. The two companies believe that leveraging NetraMark's NetraAI platform to identify key patient subpopulations can help Worldwide deliver insights to improve its clients’ clinical activities and enhance trial efficiency.
The company’s partnership with Worldwide is non-exclusive and NetraMark continues to form additional partnerships with other CROs and pharmaceutical companies as it boosts awareness of its capabilities and demonstrates proof-of-concept benefits of its technology solutions. The market opportunity within both the CRO and pharma spaces is substantial, with more than 2,800 CROs operating in the U.S. alone, according to ThermoFisher Scientific.
Partnerships with Pharmaceutical Companies…
This week, NetraMark signed a contract with Asklepion Pharmaceuticals to use the NetraAI platform to analyze results from Asklepion’s Phase III pediatric clinical trial, CIT-003-01, which evaluated the efficacy of intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects. Asklepion expects NetraMark’s AI analytics can help the pharma company demonstrate the benefits of L-citrulline in specific patient subgroups. NetraMark’s analysis for Asklepion will focus on identifying subpopulations of patients most likely to benefit from treatment to inform study designs for developing L-citrulline going forward.
In addition, NetraMark and AlgoTherapeutix announced an agreement to use the NetraAI platform to analyze patient-level data from AlgoTx’s ATX01 program. AlgoTx is a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN). The NetraAI technology will analyze drug and placebo response variables, among other factors, to inform the design of and optimize future ATX01 trials, with the goal of accelerating development timelines and potentially lowering total costs.
…and expanding solutions offerings
The company’s product portfolio leverages its proprietary AI, NetraAI, which is designed to help drug developers understand various aspects of their data, including the complexities of patient populations. The company’s models improve the understanding of how patients relate to one another and produce insights to help prevent trial failure.
The company is also developing expanded capabilities that can provide insights crucial to optimizing trial designs and execution. For example, NetraMark recently formed a collaboration with Pentara, a services company that offers clinical data analysis services to the pharmaceutical and biotechnology industries. The two companies intend to launch an intelligence tool to help optimize clinical trial activities using advanced AI-driven anomaly detection to derive a Paradox Risk score. Clinical trials generally are conducted at multiple sites, recruiting patients to participate in the trial. The Paradox Risk score expands the company’s product offerings. The partners expect it can help drug sponsors and CROs gain insight if certain sites deviate from the overall mean and potentially improve aspects of the trial design, including pre-trial site selection and active trial site reporting, among other potential benefits.
With this new tool, NetraMark capabilities will include identifying sites participating in a study that exhibit anomalous participant behavior, as well as the existing tools that identify patient subpopulations that can negatively impact trial results. The company expects this tool can help accelerate its growth and backlog conversion over time, as the CEO recently outlined in a chat with Zacks. With 1) billions of dollars spent on clinical activities to attain regulatory approval for a novel therapy and 2) the low success rate of ultimately attaining regulatory approval, we believe there is significant potential for technology that can help derisk and optimize clinical R&D spending.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.